, Tracking Stock Market Picks
Enter Symbol:
Keryx Biopharmaceuticals, Inc. (KERX) [hlAlert]

up 159.41 %

Keryx Biopharmaceuticals, Inc. (KERX) rated Buy with price target $27 by ROTH Capital

Posted on: Friday,  Feb 27, 2015  10:25 AM ET by Roth Capital

Roth Capital rated Buy Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on 02/27/2015. Previously Roth Capital rated Buy Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on
02/25/2010., when the stock price was $2.39. Since then, Keryx Biopharmaceuticals, Inc. has gained 159.41% as of 01/12/2016's recent price of $6.20.
If you would have followed the previous Roth Capital's recommendation on KERX, you would have gained 159.41% of your investment in 2147 days.

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/23/2015 2:25 PM Buy
9.45 11.00
as of 8/27/2015
1 Week down  -0.95 %
1 Month down  -38.36 %
3 Months down  -39.33 %
1 YTD down  -52.12 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/27/2015 10:25 AM Buy
11.78 27.00
2/25/2010 8:25 AM Buy
2.39 7.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy